Compare MCI & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | ASMB |
|---|---|---|
| Founded | 1971 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.7M | 440.0M |
| IPO Year | N/A | 2010 |
| Metric | MCI | ASMB |
|---|---|---|
| Price | $19.27 | $28.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $43.40 |
| AVG Volume (30 Days) | 19.6K | ★ 94.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.00 | $7.76 |
| 52 Week High | $23.79 | $39.71 |
| Indicator | MCI | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 31.54 | 46.78 |
| Support Level | $19.05 | $26.50 |
| Resistance Level | $21.19 | $30.66 |
| Average True Range (ATR) | 0.40 | 1.42 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 4.66 | 27.35 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.